Protein kinase C d (PKCd) regulates apoptosis in the mammary gland, however, the functional contribution of PKCd to the development or progression of breast cancer has yet to be determined. Meta-analysis of ErbB2-positive breast cancers shows increased PKCd expression, and a negative correlation between PKCd expression and prognosis. Here, we present in-vivo evidence that PKCd is essential for the development of mammary gland tumors in a ErbB2-overexpressing transgenic mouse model, and in-vitro evidence that PKCd is required for proliferative signaling downstream of the ErbB2 receptor. Mouse mammary tumor virus (MMTV)-ErbB2 mice lacking PKCd (dKO) have increased tumor latency compared with MMTV-ErbB2 wild-type (dWT) mice, and the tumors show a dramatic decrease in Ki-67 staining. To explore the relationship between PKCd and ErbB2-driven proliferation more directly, we used MCF-10A cells engineered to express a synthetic ligand-inducible form of the ErbB2 receptor. Depletion of PKCd with short hairpin RNA inhibited ligand-induced growth in both two-dimensional (2D) (plastic) and three-dimensional (3D) (Matrigel) culture, and correlated with decreased phosphorylation of the ErbB2 receptor and reduced activation of Src and MAPK/ERK pathways. Similarly, in human breast cancer cell lines in which ErbB2 is overexpressed, depletion of PKCd suppresses proliferation, Src and ERK activation. PKCd appears to drive proliferation through the formation of an active ErbB2/PKCd/Src signaling complex, as depletion of PKCd disrupts association of Src with the ErbB2 receptor. Taken together, our studies present the first evidence that PKCd is a critical regulator of ErbB2-mediated tumorigenesis, and suggest further investigation of PKCd as a target in ErbB2-positive breast cancer.
INTRODUCTION
The ErbB2 oncogene is amplified or overexpressed in 20-30% of all breast cancers and is associated with decreased survival, faster relapse and increased lymph node metastasis.
1,2 Overexpression of ErbB2 leads to receptor dimerization and activation of pathways involved in tumor cell proliferation and survival, such as mitogenactivated protein kinase (MAPK), Src, and phosphatidylinositol 3-kinase. Additionally, ErbB2 is the preferred binding partner of other epidermal growth factor (EGF) receptor family members; thus, overexpression of this protein increases receptor interactions, providing an efficient link to mitogenic pathways. 3, 4 The PKC family of serine/threonine kinases consists of 10 structurally related isoforms that regulate many biological functions. [5] [6] [7] PKCd is an important regulator of epithelial cell apoptosis, which has led to the speculation that it may have a role in tumorigenesis. [8] [9] [10] [11] [12] [13] Increased expression of PKCd has been shown in colon, pancreatic and high-grade breast tumors. [14] [15] [16] Conversely, PKCd expression is decreased in some cancers including bladder and endometrial carcinoma. 17, 18 We have recently shown that PKCd functions as a tumor promoter in Rasmediated lung tumors in vivo and in K-ras-addicted human nonsmall cell lung cancer (NSCLC) cells in vitro through regulation of the Ras/MAPK pathway. 19 Likewise, studies from Keshamouni et al. 20 have implicated PKCd in regulating Ras signaling downstream of ErbB2 in breast cancer cells in vitro. PKCd has also been shown to positively regulate cell migration in several cell types, including EGF receptor-overexpressing breast cancer cells. [21] [22] [23] [24] Src is a major mediator of ErbB2 signaling, and increased activation of Src is a potential mechanism through which cancer cells can become resistant to ErbB2 therapies. 25 PKCd expression is increased in breast cancer cells resistant to tamoxifen and lapatinib, suggesting that both PKCd and Src may be necessary for ErbB2-mediated signal transduction. 26, 27 Our current studies identify PKCd as a critical regulator of ErbB2-mediated proliferation, and as a tumor promoter in a MMTV-ErbB2 transgenic mouse model of mammary gland cancer. Meta-analysis of ErbB2-positive human breast cancers reveals a negative correlation between PKCd expression and prognosis, supporting further investigation of PKCd as a potential therapeutic target.
RESULTS

Increased expression of PKCd negatively correlates with prognosis in ErbB2-positive human breast cancer
To explore the contribution of PKCd to human breast cancer, we used the Oncomine database, 28 to interrogate 21 ErbB2-positive human breast cancer data sets (nX2000 patients) for PKCd mRNA expression. Our analysis shows that PKCd is significantly overexpressed in ErbB2-positive human breast cancers (Figure 1a, red; P ¼ 0.01). As ErbB2 is associated with a poor prognosis, 1,2 we determined whether increased PKCd expression affects clinical outcome specifically in patients with ErbB2-positive human breast tumors. Using the GOBO tool, 29 we performed a meta-analysis of relapse-free survival in four breast cancer data sets, where 122 patients were identified as ErbB2-positive using the PAM50 array. 30 Strikingly, high expression of PKCd (red line) significantly correlated with decreased relapse-free survival compared with low PKCd expression (gray line) (P ¼ 0.017) (Figure 1b) . Similar results were seen when we examined the correlation between PKCd mRNA expression and relapse-free survival over all molecular subtypes (P ¼ 0.0002) (Figure 1c ). In contrast, there was no correlation between PKCd mRNA expression and relapse-free survival in patients with the triple-negative tumor subtype (negative for ER, PR and ErbB2 (P ¼ 0.488) (Figure 1d) ); moreover, PKCd mRNA expression was significantly decreased in 13 triple-negative tumor data sets (Oncomine, data not shown). These results suggest that PKCd may be a significant factor in the progression of ErbB2-driven breast tumors.
Loss of PKCd increases tumor latency in MMTV-ErbB2 transgenic mice To directly address the functional role of PKCd in ErbB2-driven tumors, we utilized a transgenic mouse model in which mammary gland tumorigenesis is driven by overexpression of the wild-type rat ERBB2 gene under control of the mouse mammary tumor virus (MMTV) promoter. 31, 32 MMTV-ErbB2 mice were crossed with dKO mice to generate MMTV-ErbB2;dWT and MMTV-ErbB2;dKO mice. Both MMTV-ErbB2;dWT and MMTV-ErbB2;dKO mice developed focal mammary tumors consistent with the MMTV-ErbB2 phenotype; 31, 32 however, MMTV-ErbB2;dKO mice had a significant delay in tumor onset, with a mean latency of 293 days compared with 243 days in MMTV-ErbB2;dWT mice (P ¼ 0.03) (Figure 2A ). Mammary gland tumors were never detected in aged dKO mice (41 year of age; data not shown). Histological analysis showed that both MMTV-ErbB2;dWT and MMTV-ErbB2;dKO tumors were highly vascularized and consisted of uniform solid sheets of cells ( Figure 2B , panels a and b).
To explore the mechanism underlying increased tumor latency in MMTV-ErbB2;dKO mice, we assayed apoptosis and proliferation by immunohistochemistry for cleaved caspase-3 and Ki-67, respectively. Very few apoptotic cells were observed in tumors from either genotype ( Figure 2C ). In contrast, Ki-67-positive cells were reduced by 450% in MMTV-ErbB2;dKO tumors compared with MMTV-ErbB2;dWT tumors ( Figure 2D ), suggesting that increased tumor latency is due, at least in part, to reduced ErbB2-driven proliferation. Consistent with this finding, tumor lysates from MMTV-ErbB2;dKO mice show decreased levels of ErbB2 receptor phosphorylation compared with WT, suggesting that PKCd regulates ErbB2 signal transduction ( Figure 2E ).
PKCd is required for ErbB2-driven proliferation To explore more directly the contribution of PKCd to ErbB2-driven proliferation and tumorigenesis, we utilized a derivative of the non-transformed human breast epithelial line, MCF-10A, engineered to express a synthetic ligand-inducible form of the ErbB2 receptor (10A.ErbB2). 33, 34 In this model, the addition of an ErbB2 dimerization ligand induces ErbB2 signaling, resulting in abnormal acinar growth that resembles human ductal carcinoma in situ. 35 To find out whether PKCd contributes to this ErbB2-induced morphogenesis, 10A.ErbB2 cells were depleted of PKCd using lentiviral delivered short hairpin RNA (shRNA) targeted to PKCd (shd193 and shd203), or a scrambled control (shSCR), and grown on Matrigel for 6 days ( Figure 3A , panels a-c). In the absence of the ligand, all cells formed small, round, organized acini typical of normal MCF-10A growth ( Figure 3A , panels a-c). 36 The acini were then treated with the ligand for 3-8 days. Dimerization of ErbB2 resulted in misshapen acini in shSCR, shd193 and shd203 cells ( Figure 3A , panels g-I, m-o, insets); however, no consistent changes were seen in acini derived from shd193 and shd203 cells compared with shSCR cells. In contrast, acinar size appeared to be reduced in shd193 and shd203 cells treated with ligand compared with shSCR cells ( Figure 3A , panels g-i, m-o, insets). Indeed, quantification of the structure area showed a significant decrease in acinar size in cells depleted of PKCd as early as 3 days, which persisted through at least 8 days of growth (Figures 3A, panels g-i, m-o and 2B). In the absence of the ligand, there were no significant differences in acinar size between shd193, shd203 and shSCR cells, suggesting that PKCd is required specifically for ErbB2-driven proliferation ( Figure 3B ). To find out whether the decrease in acinar area correlated with reduced proliferation, control 10A.ErbB2 cells (shSCR) or 10A.ErbB2 cells depleted of PKCd (shd193 or shd203) were plated on Matrigel (three-dimensional (3D) culture), or as monolayers on plastic (twodimensional (2D) culture) and cell number was quantified. The addition of ligand significantly increased the total number of shSCR cells grown as 3D acini ( Figure 3C ) and as monolayers ( Figure 3D ) compared with untreated cells. For shSCR cells, the ligand-induced increase in cell number (Figures 3C and D) was considerably more robust than the increase in acinar area ( Figure 3B ), suggesting that additional mechanisms may contribute to acinar size. In contrast, in ligand-treated cells depleted of PKCd (shd193 and shd203), no increase in cell number was detected under either growth condition ( Figures 3C and D) , suggesting an absolute requirement of PKCd in ErbB2-induced proliferation.
Loss of PKCd attenuates ErbB2 signal transduction Our studies suggest that PKCd is necessary to activate ErbB2 proliferative pathways; to determine how PKCd regulates ErbB2 signaling, we treated 10A.ErbB2 cells in 3D culture ( Figure 4a ) and 2D culture (Figure 4b ) with ligand and analyzed the activation of key signaling molecules. Addition of ligand to 10A.ErbB2 shSCR cells in 3D or 2D culture resulted in robust phosphorylation at two major ErbB2 autophosphorylation sites, Y1221/1222 and Y1248 that couple ErbB2 to the Ras/MAPK pathway through the binding of Shc and companion adapter proteins, and at Y877 that has been shown to regulate the intrinsic kinase activity of ErbB2. [37] [38] [39] [40] In cells depleted of PKCd (shd193 and shd203), ligand-induced autophosphorylation of ErbB2 Y1221/ 1222 and Y1248 was slightly reduced, whereas phosphorylation of ErbB2 at Y877 was more dramatically reduced (Figures 4a and b, graphs). 40 Of note, total ErbB2 receptor protein was decreased in the absence of ErbB2 dimerization in shSCR cells, consistent with the findings that ErbB2 activation can decrease receptor turnover and stability. [41] [42] [43] As depletion of PKCd reduced phosphorylation of ErbB2 Y1221/ 1222, Y1248 and Y877, phosphorylation of downstream proteins was analyzed to determine signaling pathways regulated by PKCd. Phosphorylation of ErbB2 has been shown to recruit the adapter protein Shc, which can also signal through the Ras/MAPK pathway. 39, 44, 45 However, only a small decrease in the level of pShc Y239/40 was observed in shd193 and shd203 cells compared with that in shSCR cells in 3D culture (Figure 4a ), whereas no consistent decrease was observed under 2D culture conditions ( Figure 4b ). Further studies have not detected a difference in the phosphorylation of Shc Y317 or GAB2, both of which have been implicated in downstream signaling through ErbB2 (data not shown). These results suggest that decreased signaling through pShc is unlikely to contribute to the decrease in pERK and proliferation seen with the depletion of PKCd. Src is recruited to ErbB2 through sequences surrounding the ErbB2 Y877 residue and is thought to be responsible for phosphorylation at this site. 40, 46 . 47, 48 Concomitant with reduced phosphorylation of ErbB2 at Y877, activation of Src, as indicated by phosphorylation at Y416, was dramatically suppressed in ligand-treated shd193 and shd203 cells compared with shSCR cells (Figures 4a and b) . Quantitation by densitometry showed that in 3D and 2D culture, phosphorylation of Src Y416 was reduced by 50-80% in shd193 and shd203 cells compared with that in shSCR cells, which correlated with a 30-60% decrease in ErbB2 phosphorylation at Y877 (Figures 4a and b, graphs) . Activation of Src regulates proliferative signaling through the Ras/MAPK pathway. [49] [50] [51] As seen in Figures 4a and b , phosphorylation of ERK is dramatically reduced in cells depleted of PKCd, suggesting a mechanism by which PKCd suppresses ErbB2-driven proliferation. Decreased activation of Src, combined with the reduced phosphorylation of ErbB2 Y877, suggests that PKCd may be required for interaction of Src with the ErbB2 receptor. To address this possibility, 10A.ErbB2 cells depleted of PKCd were treated with ligand, immunoprecipitated with antibodies to the HA-tagged ErbB2 receptor, and probed for HA, PKCd and Src. In the presence of ligand, Src was found to associate with the ErbB2 receptor in shSCR cells, supporting previous findings that activation of ErbB2 requires Src (Figure 4c ). PKCd was also found to immunoprecipitate with the ErbB2 receptor, and the binding of Src to the ErbB2 receptor was disrupted in cells depleted of PKCd, demonstrating that PKCd is required for the formation of an active ErbB2 signaling complex.
PKCd regulates proliferation in ErbB2-overexpressing human breast cancer cells We next examined the contribution of PKCd to ErbB2-regulated proliferation in human breast cancer cells that overexpress ErbB2.
Depletion of PKCd with shd193 or shd203 in MDA-MB-361, BT-474, and ZR-75-30 cells significantly reduced proliferation compared with shSCR control cells ( Figure 5A ). The largest decrease in proliferation was observed in BT-474 cells, where proliferation was reduced by 59 and 38% in shd193 or shd203 cells, respectively. These results correspond to the relative depletion of PKCd ( Figure 5A , PKCd insets). Analysis of ErbB2-mediated signaling showed that both Src and ERK phosphorylation were decreased in shd193 and shd203 cells compared with that in shSCR in all three cell lines, similar to that seen in 10A.ErbB2 cells ( Figure 5B) . Interestingly, in all cell lines, the total level of Src appeared to be slightly reduced, a result that was not seen in 10A.ErbB2 cells, suggesting that PKCd may regulate Src stability or turnover in breast cancer cells.
To determine if PKCd regulates ErbB2-driven proliferation through the MAPK pathway, MDA-MB-361 and BT-474 cells with PKCd knockdown were transduced with an adenovirus that expresses constitutively activated MEK (CA-MEK). Expression of Figure 4 . Loss of PKCd attenuates ErbB2 signal transduction. For all panels: PKCd was depleted using lentiviral shRNA constructs (shd193 and shd203) and compared with control shRNA (shSCR) as described in Materials and Methods. (a and b) . 10A.ErbB2 cells depleted of PKCd were plated in 3D culture (a) or 2D culture (b) and then treated for 3 days or 24 h with ligand respectively. Protein expression and phosphorylation in whole cell lysates was evaluated by immunobloting. The following antibodies were used: pErbB2 (Y877, Y1221/1221, Y1248); ErbB2; pSrc (Y416); Src; pShc (Y239/240); Shc, pErk1/2 (T202/Y204); Erk1/2; PKCd; and actin. Immunoblots probed for phosphorylated proteins were stripped and probed with antibodies to total protein, as indicated. Blots were probed for actin as a loading control. Relative PKCd knockdown compared to shSCR is shown in boxed region below blots. Immunoblots were quantified by densitometry; graphs depict the levels of phosphorylated pErbB2 Y877 and pSrc Y416 over total protein levels upon ligand treatment. Representative experiments shown; experiments were repeated a minimum of three times. (c). 10A.ErbB2 cells depleted of PKCd were treated for 24 h with ligand. Cells were lysed and ErbB2 was immunoprecipitated with anti-HA primary antibody. Immunoprecipitated protein was resolved on an SDS-PAGE gel and probed for HA, PKCd and Src. Lysates were incubated with a non-specific mouse IgG as a negative control (NEG). Whole cell lysates (WCL) were probed for HA, PKCd and Src. Actin was used as a loading control. Representative experiments shown; experiments were repeated a minimum of three times.
CA-MEK activated ERK and significantly rescued the reduction in proliferation seen with the loss of PKCd in shd193 and shd800 cells ( Figure 5C, panel a) . Similarly, when PKCd was re-expressed in MDA-MB-361 cells depleted of PKCd (shd800), proliferation was rescued ( Figure 5C , panel b), and this rescue was significantly reduced by pretreatment with the ERK inhibitor, PD98059. Together, these results indicate that PKCd specifically regulates ErbB2 signaling through activation of the MAPK pathway.
DISCUSSION
Our studies reveal PKCd as a major regulator of ErbB2-mediated proliferation in breast cancer. Analysis of human ErbB2-positive breast cancer tumor samples shows a negative correlation between PKCd expression and relapse-free survival. Using a mouse model of ErbB2-dependent mammary gland tumorigenesis, we show that loss of PKCd significantly increases tumor latency and suppresses tumor cell proliferation. Further, studies in human breast cancer cell lines support these findings and suggest that PKCd is essential for the activation of Src and ERK downstream of the ErbB2 receptor. Together, these findings implicate PKCd as a tumor promoter and a potential therapeutic target in ErbB2-overexpressing breast cancer.
We show that tumors from MMTV-ErbB2;dKO mice have reduced proliferation and altered ErbB2 activation compared with MMTV-ErbB2;dWT controls (Figure 2) , and that PKCd is necessary for the induction of ErbB2-driven proliferation in 2D and 3D culture ( Figure 3 ). An interesting observation is that depletion of PKCd has a much more dramatic effect on 3D growth of MCF10A.ErbB2 cells, compared with 2D growth. Presumably, 3D culture provides a more complex signaling system by allowing not only cell-cell interactions, but also cell-matrix interactions, that are lacking in cells grown on plastic. We observed a similar phenomenon in lung cancer, where PKCd was required for lung tumorigenesis in vivo, and for the growth of NSCLC lines in soft agar, but not for growth on plastic. 19 Characterization of the proteins involved in ErbB2 signaling in the context of PKCd depletion revealed a decrease in phosphorylation of the ErbB2 receptor at Y1221/1222, Y1248 and Y877 (Figure 4 ). We were unable to detect a change in the activation of the adapter protein, Shc; however, loss of PKCd significantly suppressed Src activation, which likely contributes to the suppression of ERK and downstream proliferation. Phosphorylation at ErbB2 Y877 has been linked to the regulation of ErbB2's intrinsic kinase activity and loss of this phosphorylation results in a corresponding decrease in ErbB2 Y1221/1222 and Y1248 phosphorylation. 40, 46, 52 These results suggests that the ErbB2 receptor may have decreased activity in cells lacking PKCd, and that decreased autophosphorylation of ErbB2 at Y1221/1222 and Y1248 may be secondary to the decrease at ErbB2 Y877. Additionally, total ErbB2 levels decreased in response to EGF starvation (Figure 4a, ligand) , and addition of the ErbB2 dimerization ligand restored ErbB2 expression. Cells with PKCd knockdown have decreased expression of the ErbB2 receptor in response to dimerization compared with scrambled controls, indicating that either PKCd regulates the stability of the receptor or that PKCd effects ErbB2 translation. Further studies have to be performed to directly explore this regulation.
Several reports have intimately linked Src with the phosphorylation of ErbB2 Y877. 40, 46 Marcotte et al. 46 demonstrated that Src associates with the ErbB2 receptor through sequences surrounding ErbB2 Y877 and is required for ErbB2 Y877 phosphorylation. Correspondingly, in our studies, depletion of PKCd results in a loss of Src activation (phosphorylation at Y416) and binding to the ErbB2 receptor, suggesting that PKCd is required for the formation of an active ErbB2 signaling complex with Src (Figure 4c ). Reduced signaling through ErbB2/Src is likely the mechanism by which depletion of PKCd suppresses ERK activation and proliferation. It is not clear from our current studies whether ErbB2 or Src are PKCd kinase substrates; alternatively, PKCd may function as a scaffold in this complex. In NSCLC cell lines, ERK activation can be inhibited by expression of a kinaseinactive form of PKCd, suggesting that the kinase activity of PKCd is important for the activation of this proliferative pathway. 19 Limited studies in human breast cancer tissue and cell lines suggest that elevated PKCd may correlate with more aggressive breast cancer.
14,22 Our analysis shows that PKCd expression is significantly increased in ErbB2-positive versus -negative human breast tumors. High expression of PKCd also significantly correlates with decreased relapse-free survival in ErbB2-positive human breast cancer patients (Figure 1) , supporting a role for PKCd in the regulation of ErbB2-driven tumor formation. Further, a broad analysis of relapse-free survival over all molecular subtypes indicates that high PKCd expression persistently correlates with a significant negative clinical outcome. Notably, this correlation does not appear to hold true across all subtypes, as our metaanalysis indicates that PKCd expression is decreased in triplenegative breast cancers with no significant change in relapse-free survival (Figure 1) . Interestingly, it has been proposed that ErbB2-overexpressing breast cancer cells can confer therapeutic resistance through an upregulation of Src activation. 25 Moreover, Rexer et al. 26 show that lapatinib-resistant cells contain increased levels of PKCd phosphorylation at Y313, a site known to be phosphorylated by Src, compared with sensitive cells. Similarly, our current data indicate that PKCd increases the occurrence of tumor relapse in ErbB2-positive tumors.
In contrast to numerous studies from our lab and others that demonstrate a pro-apoptotic function for PKCd, 12,53-55 our current studies indicate a pro-proliferative role for PKCd in breast cancer. Likewise PKCd has also been shown to regulate proliferation in murine mammary cells, in mouse models of pancreatic and lung cancer, and in human NSCLC cells. 19, 56, 57 Our studies specifically implicate PKCd in regulating the MAPK pathway downstream of ErbB2 ( Figure 5C ). We propose that in some oncogenic contexts, the function of PKCd may switch from pro-apoptotic to prosurvival. In this regard, NSCLC cells addicted to oncogenic K-ras appear to utilize PKCd as a proliferative signal, whereas non-K-ras addicted NSCLC cell lines may preferentially utilize PKCd for apoptosis 19 (and unpublished data). Taken together, our studies suggest a unique regulatory mechanism by which PKCd regulates ErbB2 signal transduction ( Figure 5D ). We show that in cells in which ErbB2 is activated, Src and ErbB2 are found in a complex. This association correlates with increased phosphorylation of ErbB2 at Y877, Y1221/1222 and Y1248, and increased proliferation. Loss of PKCd disrupts this complex, resulting in decreased association of Src with the ErbB2 receptor, as well as a decrease in ErbB2 and Src activation. As Src is responsible for the phosphorylation of ErbB2 Y877, a site that has been associated with maintaining ErbB2 activity, loss of Src binding to the ErbB2 receptor ultimately leads to an attenuation of ErbB2-driven proliferation. Together, these studies support a critical role for PKCd in the regulation of ErbB2 signaling and proliferation both in vivo and in vitro ,and support future investigation of PKCd as a therapeutic target in human breast cancer.
MATERIALS AND METHODS
Animal model
FVB PKCd KO mice (dKO) have been previously described. 19 MMTV-ErbB2 (line 202) transgenic mice 32 were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and crossed to FVB dKO mice. Genotypes were determined by PCR using primers for the ErbB2 transgene (forward primer (Neu-3) 5 0 -CGGAACCCACATCAGGCC-3 0 ; reverse primer (Neu-4) 5 0 -TTTCCT GCAGCAGCCTACGC-3 0 . Animals were maintained at the University of Colorado Denver, Anschutz Medical Campus in accordance with Laboratory Animal Care guidelines and protocols and approved by the Institutional Animal Use and Care Committee. Virgin MMTV-ErbB2;dWT and MMTV-ErbB2;dKO mice were palpated weekly for mammary tumors, starting at 120 days of age. MMTV-ErbB2;dWT littermates were used for all studies. Tumors were harvested after they attained a size of 1 cm in diameter, fixed in 10% neutral buffered formalin, processed and paraffinembedded for sectioning.
Cell lines and reagents MCF10A.ErbB2 (10A.ErbB2) cells were a generous gift from Senthil Muthuswamy and previously described. 33, 34 10A.ErbB2 cells were kept in growth media (Dulbecco's modified Eagle medium/F12 (HyClone, Thermo Fisher Scientific, Logan, UT, USA) supplemented with 5% donor horse serum (Gibco, Grand Island, NY, USA), 20 ng/ml EGF (BD Transduction Laboratories, Bedford, MA, USA), 10 mg/ml insulin (Gibco), 1 ng/ml choleratoxin (Thermo Fisher Scientific), 100 mg/ml hydrocortisone and 200 mg/ml active G418 (Gibco). The ErbB2 dimerizers (ligand), AP1510 (Ariad, Cambridge, MA, USA) and B/B homodimer (Clontech, Mountain View, CA, USA) were used at 250-500 nM for 2D cell culture and 1 mM for 3D cell culture. Growth factor-reduced Matrigel was purchased from BD Transduction Laboratories. Human breast cancer lines were obtained from the University of Colorado Denver Cancer Center Tissue Culture Core.
Microarray data analysis
Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) was used for the analysis of mRNA expression data from 21 human breast cancer studies. 28 Methods of normalization and statistical calculations are provided on the Oncomine website (www.oncomine.org). Gene expression was compared within ErbB2-positive versus -negative tumors. Differential expression of the individual genes analyzed was then ranked by P-value across each data set, with a rank of one being the most significantly changed gene in ErbB2-positive tumors. The median rank of PKCd was calculated across all 21 data sets and analyzed for significance of overexpression or underexpression. Similar analysis was used to determine PKCd expression in triple-negative tumors versus all other molecular subtypes. GEO accession numbers or paper references for the 21 datasets are as follows: (1) Meta-analysis of PKCd gene expression and correlation with clinical relapse-free survival was analyzed over four data sets (GSE7390, GSE3494, GSE1456 and GSE6432) encompassing 914 individual tumors using the GOBO tool (http://co.bmc.lu.se/gobo) as previously described. 29 ErbB2-enriched tumors were identified from the four data sets (listed above) through the PAM50 gene set signature and represent 122 individual tumors, whereas basal tumors represent 143 tumors. 30 PKCd depletion and reconstitution Stable depletion of PKCd was achieved using lentiviral constructs containing shRNA to human PKCd (pLKO-TRC00010193 (shd193), pLKO-TRC00010203 (shd203) or pLKO-TRCN0000284800 (shd800)) or a shRNA control (pLKO-scrambled (shSCR)) (Open Biosystems, Huntsville, AL, USA or Sigma-Aldrich, St Louis, MO, USA) as previously described. 19 Adenovirus expression of LacZ, PKCd or CA-MEK was performed as previously described. 60 Adenovirus transduction efficiency was 495% as verified by visualization of GFP-tagged protein by fluorescent microscopy.
Immunohistochemistry
For immunohistochemistry, the sections were exposed to citrate buffer and heat antigen retrieval and then blocked with avidin and biotin. Endogenous peroxidase was quenched with 3% H 2 O 2 . The sections were incubated with primary antibody for 1 h at room temperature (anti-cleaved caspase-3 and KI-67). Primary antibodies include anti-cleaved caspase-3 (1:100; Cell Signaling Technology, Beverly, MA, USA) and anti-Ki-67 (1:50; DakoCytomation, Carpinteria, CA, USA). The sections were incubated in appropriate secondary antibodies for 30 min at room temperature. Sections were incubated with Vectastain ABC Reagent (Vector Laboratories, Burlingame, CA, USA) for an additional 30 min at room temperature. The signal was detected with diaminobenzadine substrate (Sigma-Aldrich) and tissues were counterstained with Gill's hematoxylin. For quantification of Ki-67 and cleaved caspase-3 staining, tumor sections were scanned using Aperio hardware and software (Vista, CA, USA). Six to eight fields were outlined (per tumor, per genotype), which encompassed the majority of non-border and non-necrotic regions of each tumor section. Staining was quantified and expressed as the percent of positive cells utilizing the Aperio color deconvolution algorithm (Aperio). n ¼ 5 MMTV-ErbB2;dWT, 4 MMTV-ErbB2;dKO.
3D morphogenesis assay
Growth factor-reduced Matrigel (40 ml) was plated on eight-well chamber slides (nos. 354230 and 354118; BD Transduction Laboratories) and allowed to solidify for 415 min at 37 1C. 10A.ErbB2 cells (5000 cells/well) were trypsinized and resuspended in plating media (Dulbecco's modified Eagle medium/F12 supplemented with 2% donor horse serum, 10 mg/ml insulin, 1 ng/ml cholera toxin, 100 mg/ml hydrocortisone, 5 ng/ml EGF and 200 mg/ml active-G418) with 2% Matrigel. On day 5, cells were switched to assay media without EGF and 24 h later, cells were left untreated or treated with ligand (1 mM). Ligand was replenished every 2 days. Cells were imaged live on day 6, 9, and 14 using the Zeiss Observer.Z1 microscope (Thornwood, NY, USA) and captured using Volocity 6.0 software (Perkin Elmer, Waltham, MA, USA). Of each condition, Â 5 binary pictures were then used to quantify structure area using MetaMorph software (Molecular Devices, Sunnyvale, CA, USA); nX200 structures, representative of three experiments shown.
2D and 3D growth curves For 2D culture growth curves, BT-474, MDA-MB-361, ZR-75-30 and 10A.ErbB2 cells expressing either shRNA to PKCd (shd193 and shd203) or a scrambled control (shSCR) were plated at equal densities. 10A.ErbB2 cells were plated in growth media. Twenty-four hours after plating, the media was changed to assay media, and 48 h after plating, the cells were treated with ligand in assay media. For 3D growth curves, 10A.ErbB2 cells were grown as described above (3D morphogenesis assay). Three days after the addition of ligand, acini were treated with 0.25% trypsin for 1 h at 37 1C and cells were counted by hemocytometer.
Immunoblot analysis
For 3D cultures, acini were washed in ice-cold PBS, then treated with lysis buffer for 1 h at 4 1C with continuous shaking. Lysates were spun at 12 500 r.p.m. for 20 min at 4 1C, and supernatants from 2D and 3D culture were then separated by SDS-PAGE and immunoblotting as previously described. 61 Anti-PKCd (C-20) was purchased from Santa Cruz Biotechnology (sc-937 Santa Cruz, CA, USA). The following antibodies were purchased from Cell Signaling Technologies: phospho-ErbB2 (Tyr877) (no. 2241; pErbB2 Y877); phospho-ErbB2 (Tyr1221/1222) (no. 2249; pErbB2 Y1221/1222); ErbB2 (no. 2165); phospho-Src Family (Tyr416) (no. 2101; pSrc); Src (no. 2108); phospho-Shc (Tyr239/240) (no. 2434; pShc); Shc (no. 2432); phospho-ERK1/2 (no. 9101; pERK1/2); and ERK1/2 (no. 4695). Phospho-ErbB2 (Tyr1248) (ab47755) and actin-HRP (ab49900) were purchased from Abcam (Cambridge, MA, USA). Densitometry was performed using UVP VisionWorks LS software (UVP, Upland, CA, USA).
Immunoprecipitation
10A.ErbB2 cells were placed in media without EGF for 24 h, and then treated with ErbB2 ligand (B/B homodimer, 250 nM) for 2 h. Immunoprecipitation was performed as previously described. 61 Five-hundred microgram of protein was incubated with primary antibody (2 mg; anti-HA; no. MMS-101, Covance, Princeton, NJ, USA) or control (2 mg; anti mouse IgG; no. 2025; Santa Cruz Biotechnology) for 3 hours at 4 1C. Immunoblots were probed with the following antibodies: anti-HA (no. MMS-101, Covance), Src (no. 8056, Santa Cruz) and PKCd (no. sc-937 Santa Cruz Biotechnology).
